All News
ICYMI: New Laboratory Insights for the ANA+ Consult
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
Read Article
ICYMI: RA Disease Activity and Alcohol Use
Despite its well known toxicities, alcohol is known to be antiinflammatory. The effects of alcohol use in rheumatoid arthritis (RA) is less known, but a recent study suggests that alcohol consumption was dose-dependently associated with lower disease activity and higher health-related quality of life in RA patients.
Read Article
JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023
Dr. John Cush RheumNow ( View Tweet)
Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/0B1zzeqm1L
Links:
Dr. John Cush RheumNow ( View Tweet)
Check SSc-ILD Patients on Nintedinib for Malnutrition
During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.
https://t.co/TmN71qSCb2 https://t.co/TVU2qcPdZE
Links:
Dr. John Cush RheumNow ( View Tweet)
2022 of fibromyalgia Year in review discusses possible causes (inflammation, gut dysbiosis, neuroinflammation), new Rx (kinin antagonists, neurostimulation, mind-body Rx; but more needed on ketamine, vitamin D, and hormonal therapy https://t.co/sya8fSCbFX https://t.co/F2HDcp2XYb
Links:
Dr. John Cush RheumNow ( View Tweet)
Paradoxical PsO (PP) studied in 2867 RA & 5316 SpA pts. 136 (1.7%) had paradox. Rxn, median 12 mos post TNFi [pustular (60%) or palmoplantar (31%)]. 73% PP favorably switched to other TNFi 46% or non-TNFi 27%. RA PP took SSZ, HCQ, LEF; SpA PP more smokers https://t.co/w1EQEvHbeG https://t.co/aAwKxdNYk1
Links:
Dr. John Cush RheumNow ( View Tweet)
Paradoxical Psoriasis in Kids Taking TNF Inhibitors
A multicenter cohort study reported a large cohort of pediatric patients receiving TNF inhibitor therapy complicated by psoriasis, regardless of treatment indication or the specific TNF inhibitor.
https://t.co/9WxkAt8NnS https://t.co/sGvb1eZWE0
Links:
Dr. John Cush RheumNow ( View Tweet)
TitAIN Study: Secukinumab Efficacy in Giant Cell Arteritis
A phase 2 trial has demonstrated the efficacy of secukinumab, an anti-interleukin-17A monoclonal antibody, in patients with active giant cell arteritis (GCA).
https://t.co/rmYBXBV3RP https://t.co/q1CfhuGSj7
Links:
Dr. John Cush RheumNow ( View Tweet)
Belimumab in adult inflamm myositis (IIM)? Small study 15 IIM pts recv ≥ 5 doses of belimumab or placebo; Treatment success (TIS ≥ 40) was more common with BEL (55% vs 33%) as was defined improvement (DOI: 33% vs 17%); not signif, but interesting! https://t.co/3xL0ylJbcs https://t.co/Oerf0yI4Jg
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has approved a 2nd JAK inhibitor for Alopecia areata - Pfizers Ritlecitinib (Litfulo) is approved for Adults and Adolescents (>12 yrs) With Severe Alopecia Areata (based on ALLEGRO trial, pub in Lancet) https://t.co/Uods58glJG https://t.co/Uods58glJG https://t.co/syCqnG6sLg
Dr. John Cush RheumNow ( View Tweet)
PRE-CLINICAL RA: What do you need to better manage pre-clinical (at-risk) Rheumatoid arthritis Patients? Rheumatologists vote here >>https://t.co/lt38vJMEIA
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s new Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available.
https://t.co/38foNET3j4 https://t.co/8CjXwzyGab
Links:
Dr. John Cush RheumNow ( View Tweet)
In pts seeking care for MSK pain cannot assume that improving pain/function will result in improved depression, but substantial improvements are required to effect anxiety. Study of 11 236 Ortho pts in JAMA https://t.co/5vvoPs31GU https://t.co/gEwZNW35xB
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of FDA review times for New Indication Approvals of Drugs and Biologics (2017 - 2019) finds FDA approved 107 drugs for 146 new indications [99 small molecules (68%) & 47 biologics (32%)]. Median regulatory review time was 6 mos (IQR, 6-10) https://t.co/3P6T4R4FCF https://t.co/avl65W3kvr
Links:
Dr. John Cush RheumNow ( View Tweet)
UK MHRA reminder that NSAIDs are:
- contraindicated in the 3rd trimester of pregnancy (>28wks)
- >20 wks - assoc w/ increased risk of oligohydramnios & fetal renal dysfunction
MDs should avoid NSAIDs in pregnancy after wk 20 https://t.co/u3fTnuoF17 https://t.co/b2b5XThe1i
Links:
Dr. John Cush RheumNow ( View Tweet)
Predictors of Cardiovascular Events in ANCA-Associated Vasculitis
A large, retrospective, multinational study of patients with ANCA-AAV shows they may be at risk for CVEs.
https://t.co/k9XPolEXKc https://t.co/0nxai3Eqe2
Links:
Dr. John Cush RheumNow ( View Tweet)
Check SSc-ILD Patients on Nintedinib for Malnutrition
During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.
https://t.co/5Q3xCwLvPa https://t.co/mGD3DCYZR0
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow LIVE VOTE Survey:
What do you need to better manage pre-clinical (at-risk) Rheumatoid arthritis? Please vote here >>https://t.co/lt38vJMEIA
Links:
Dr. John Cush RheumNow ( View Tweet)
Comprehensive, full-read overview of SLE treatment with Tyk2 vs JAK inhibitors https://t.co/KjLEYGfxAY https://t.co/btvoBQjboi
Links:
Dr. John Cush RheumNow ( View Tweet)